144 related articles for article (PubMed ID: 16563003)
21. Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models.
Boppana K; Dubey PK; Jagarlapudi SA; Vadivelan S; Rambabu G
Eur J Med Chem; 2009 Sep; 44(9):3584-90. PubMed ID: 19321235
[TBL] [Abstract][Full Text] [Related]
22. Pharmacophores incorporating numerous excluded volumes defined by X-ray crystallographic structure in three-dimensional database searching: application to the thyroid hormone receptor.
Greenidge PA; Carlsson B; Bladh LG; Gillner M
J Med Chem; 1998 Jul; 41(14):2503-12. PubMed ID: 9651155
[TBL] [Abstract][Full Text] [Related]
23. Virtual screening studies to design potent CDK2-cyclin A inhibitors.
Vadivelan S; Sinha BN; Irudayam SJ; Jagarlapudi SA
J Chem Inf Model; 2007; 47(4):1526-35. PubMed ID: 17523616
[TBL] [Abstract][Full Text] [Related]
24. Enhancing specificity and sensitivity of pharmacophore-based virtual screening by incorporating chemical and shape features--a case study of HIV protease inhibitors.
Pandit D; So SS; Sun H
J Chem Inf Model; 2006; 46(3):1236-44. PubMed ID: 16711743
[TBL] [Abstract][Full Text] [Related]
25. Automated generation of MCSS-derived pharmacophoric DOCK site points for searching multiconformation databases.
Joseph-McCarthy D; Alvarez JC
Proteins; 2003 May; 51(2):189-202. PubMed ID: 12660988
[TBL] [Abstract][Full Text] [Related]
26. A pharmacophore map of small molecule protein kinase inhibitors.
McGregor MJ
J Chem Inf Model; 2007; 47(6):2374-82. PubMed ID: 17941626
[TBL] [Abstract][Full Text] [Related]
27. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
Thomas MP; McInnes C
IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
[TBL] [Abstract][Full Text] [Related]
28. Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring.
Zhang Q; Muegge I
J Med Chem; 2006 Mar; 49(5):1536-48. PubMed ID: 16509572
[TBL] [Abstract][Full Text] [Related]
29. Combining pharmacophore fingerprints and PLS-discriminant analysis for virtual screening and SAR elucidation.
Askjaer S; Langgård M
J Chem Inf Model; 2008 Mar; 48(3):476-88. PubMed ID: 18281962
[TBL] [Abstract][Full Text] [Related]
30. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
[TBL] [Abstract][Full Text] [Related]
31. The impact of tautomer forms on pharmacophore-based virtual screening.
Oellien F; Cramer J; Beyer C; Ihlenfeldt WD; Selzer PM
J Chem Inf Model; 2006; 46(6):2342-54. PubMed ID: 17125178
[TBL] [Abstract][Full Text] [Related]
32. Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering.
Muthas D; Sabnis YA; Lundborg M; Karlén A
J Mol Graph Model; 2008 Jun; 26(8):1237-51. PubMed ID: 18203638
[TBL] [Abstract][Full Text] [Related]
33. A self-organizing algorithm for molecular alignment and pharmacophore development.
Bandyopadhyay D; Agrafiotis DK
J Comput Chem; 2008 Apr; 29(6):965-82. PubMed ID: 17999384
[TBL] [Abstract][Full Text] [Related]
34. Incorporating dynamics in E. coli dihydrofolate reductase enhances structure-based drug discovery.
Lerner MG; Bowman AL; Carlson HA
J Chem Inf Model; 2007; 47(6):2358-65. PubMed ID: 17877338
[TBL] [Abstract][Full Text] [Related]
35. Refinement of histamine H3 ligands pharmacophore model leads to a new class of potent and selective naphthalene inverse agonists.
Roche O; Nettekoven M; Vifian W; Sarmiento RM
Bioorg Med Chem Lett; 2008 Aug; 18(15):4377-9. PubMed ID: 18606542
[TBL] [Abstract][Full Text] [Related]
36. Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads.
Vadivelan S; Sinha BN; Rambabu G; Boppana K; Jagarlapudi SA
J Mol Graph Model; 2008 Feb; 26(6):935-46. PubMed ID: 17707666
[TBL] [Abstract][Full Text] [Related]
37. A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application.
Baroni M; Cruciani G; Sciabola S; Perruccio F; Mason JS
J Chem Inf Model; 2007; 47(2):279-94. PubMed ID: 17381166
[TBL] [Abstract][Full Text] [Related]
38. Protein flexibility and species specificity in structure-based drug discovery: dihydrofolate reductase as a test system.
Bowman AL; Lerner MG; Carlson HA
J Am Chem Soc; 2007 Mar; 129(12):3634-40. PubMed ID: 17335207
[TBL] [Abstract][Full Text] [Related]
39. Structural basis for ligand recognition at the benzodiazepine binding site of GABAA alpha 3 receptor, and pharmacophore-based virtual screening approach.
Vijayan RS; Ghoshal N
J Mol Graph Model; 2008 Oct; 27(3):286-98. PubMed ID: 18565775
[TBL] [Abstract][Full Text] [Related]
40. Minimizing false positives in kinase virtual screens.
Perola E
Proteins; 2006 Aug; 64(2):422-35. PubMed ID: 16708364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
